Gene · 2925
Papers2,036
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,036
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Evaluation of ABD-Linked RM26 Conjugates for GRPR-Targeted Drug Delivery. | ACS Omega | 2024 | 39220525 | PubTator, text mining | PubMed |
| Radiopharmaceuticals Targeting Gastrin-Releasing Peptide Receptor for Diagnosis and Therapy of Prostate Cancer. | Mol Pharm | 2024 | 39219355 | PubTator, text mining | PubMed |
| In vitro and in vivo evaluation of Bombesin-MMAE conjugates for targeted tumour therapy. | Eur J Med Chem | 2024 | 39146832 | PubTator, text mining | PubMed |
| Chromosome X-Wide Common Variant Association Study (XWAS) in Autism Spectrum Disorder. | medRxiv | 2024 | 39108515 | PubTator, text mining | PubMed |
| Targeted radionuclide therapy for gliomas: Emerging clinical trial landscape. | Neuro Oncol | 2024 | 39107236 | PubTator, text mining | PubMed |
| Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT. | J Nucl Med | 2024 | 39089814 | PubTator, text mining | PubMed |
| Aurantiamide mitigates acute kidney injury by suppressing renal necroptosis and inflammation via GRPR-dependent mechanism. | Int Immunopharmacol | 2024 | 39059099 | PubTator, text mining | PubMed |
| Bimodal MRI/Fluorescence Nanoparticle Imaging Contrast Agent Targeting Prostate Cancer. | Nanomaterials (Basel) | 2024 | 39057854 | PubTator, text mining | PubMed |
| Optimized Production of 188Re-HYNIC-Bombesin: New Therapeutic Agent for GRPR Targeting. | Nucl Med Mol Imaging | 2024 | 39036461 | PubTator, text mining | PubMed |
| Synthesis and Evaluation of the First 68Ga-Labeled C-Terminal Hydroxamate-Derived Gastrin-Releasing Peptide Receptor-Targeted Tracers for Cancer Imaging with Positron Emission Tomography. | Molecules | 2024 | 38999054 | PubTator, text mining | PubMed |
| Lessons learned in application driven imaging agent design for image-guided surgery. | Eur J Nucl Med Mol Imaging | 2024 | 38900308 | PubTator, text mining | PubMed |
| Evaluation of gastrin-releasing peptide receptor, prostate-specific membrane antigen, and neurotensin receptor 1 as potential biomarkers for accurate prostate cancer stratified diagnosis. | EJNMMI Res | 2024 | 38880858 | PubTator, text mining | PubMed |
| Effects of black bean cell wall pectin by exogenous calcium ions: Insight into the metabolomics, physicochemical properties and anti-digestive capacity. | Int J Biol Macromol | 2024 | 38876245 | PubTator, text mining | PubMed |
| Synthesis and Evaluation of Novel 68Ga-Labeled [D-Phe6,Leu13ψThz14]bombesin(6-14) Analogs for Cancer Imaging with Positron Emission Tomography. | Pharmaceuticals (Basel) | 2024 | 38794191 | PubTator, text mining | PubMed |
| Two Novel [68Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar11]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer. | ACS Omega | 2024 | 38680331 | PubTator, text mining | PubMed |
| GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics. | Pharmaceutics | 2024 | 38675174 | PubTator, text mining | PubMed |
| Biodistribution and radiation dosimetry of [99mTc]Tc-N4-BTG in patients with biochemical recurrence of prostate cancer. | EJNMMI Res | 2024 | 38668903 | PubTator, text mining | PubMed |
| Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years. | PET Clin | 2024 | 38644111 | PubTator, text mining | PubMed |
| Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer. | Ann Med | 2024 | 38442298 | PubTator, text mining | PubMed |
| 68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial. | Lancet Oncol | 2024 | 38423030 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2925/papers?page=7